Disufenton sodium is under clinical development by Oblato and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Disufenton sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Disufenton sodium overview
Disufenton sodium (NXY-059, OKN-007) is under development for the treatment of recurrent glioblastoma, high-grade glioma, oligodendroglioma, recurrent malignant glioma and glioblastoma multiforme, Diffuse Intrinsic Pontine Glioma (DIPG). It is administered through oral route and an intravenous infusion. It is a nitrone-based free radical scavenger that acts by targeting sulfatase 2 (SULF2) and free radicals. It was also under development for the treatment of acute ischemic stroke, intracerebral hemorrhage, hepatocellular carcinoma and glioblastoma multiforme.
It was also under development for the treatment of low-grade glioma and astrocytoma.
For a complete picture of Disufenton sodium’s drug-specific PTSR and LoA scores, buy the report here.